Major interest surrounds how angiotensin II triggers cardiac hypertrophy via epidermal growth factor receptor transactivation. G protein–mediated transduction, angiotensin type 1 receptor ...

Rationale: The vasoactive peptide angiotensin II (Ang II ... 2A target gene Xirp2 in Ang II–mediated cardiac remodeling was investigated. Conclusions: These findings reveal a novel MEF2A-Xirp2 pathway ...

Role of the RAAS in the Pathophysiology of Heart Failure ACE inhibitors have no effect on angiotensin II formed by alternate pathways. In contrast, ARBs would be expected to inhibit the biologic ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

Cardiac hypertrophy is the abnormal enlargement, or thickening, of the heart muscle, resulting from increases in cardiomyocyte size and changes in other heart muscle components, such as ...

SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through ...

If the same holds true for cardiac muscle, new assays are needed to accurately assess active calcineurin levels, either in hypertrophic or in failed heart tissue. The differential regulation of ...

Objectives INTRODUCTION: Angiotensin (Ang) II is known to activate matrix metalloproteinases (MMPs), leading to degradation of extracellular matrix (ECM) proteins and myocardial remodelling.

May 22, 2025 — When the workload on the heart increases, the ventricular wall may thicken too, known as cardiac hypertrophy. This is an adaptive response that reduces pressure on the heart and ...

Objective ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs ... Main outcome was rates of CV mortality, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for CV disease ...